Form 4 for STLN Starling Oncology, Inc.
Accepted 2022-12-08 00:00:00 ET · period of report 2022-12-07 · accession 0001799191-22-000056 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-12-08 | 2022-12-07 | STLN | Virnich Daniel | Pres | M - OptEx | $0.86 | +350.0K | 623.6K | +128% | +$301.0K |
| DM | 2022-12-08 | 2022-12-07 | STLN | Virnich Daniel | Pres | M - OptEx | $0.00 | -350.0K | 829.6K | -30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-07 | M | A | 175,000 | $0.86 | 448,585 | D | — | — | |
| 2 | Common | Common Stock | 2022-12-07 | M | A | 175,000 | $0.86 | 623,585 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-12-07 | M | D | 175,000 | $0.00 | 654,609 | D | $0.86 · — to 2030-03-01 | 175,000 Common Stock | (F2) These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of March 1, 2020 (the "Original Grant Date"), and as to 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date. |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-12-07 | M | D | 175,000 | $0.00 | 829,609 | D | $0.86 · — to 2030-03-01 | 175,000 Common Stock | (F1) These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination. |